Industry Policy Committee Initiatives for Research and Development
As of September 1, 2024
| Company name | Activities being undertaken in relation to intractable and rare diseases |
|---|---|
| Kyowa Kirin Co. | Promoting drug development by utilizing clinical real-world data (RWD)
In drug development for rare diseases, in addition to conducting clinical trials, we are considering the use of various RWD (observational studies/use of disease registries, etc.) in order to shorten development time and deliver drugs as soon as possible. Patient Engagement in the Creation of New Drugs
Kyowa Kirin is engaged in patient advocacy activities as part of its efforts to achieve its "New Vision for 2030. In the area of new drug research and development, Kyowa Kirin has been trying to incorporate patients' perspectives into the existing framework of "patient engagement," which is based on information from physicians, academia, and literature, and has been built on a theory-driven approach. In this effort, we are planning exchange events and other activities aimed at deepening mutual understanding between researchers and patients through direct dialogue, in order to grasp the true needs of pharmaceutical products.
We aim to provide life-changing value by reflecting the difficulties and demands of daily life that we hear about in interviews with patients in our clinical development plans. |
| Daiichi Sankyo | Initiatives through COMPASS
COMPASS (Compassion for Patients Strategy) was launched in 2014 as a cross-organizational activity within the R&D Division as part of Daiichi Sankyo's efforts to promote the realization of "patient-oriented drug discovery. Currently, based on "Compassion for Patients," which is part of Daiichi Sankyo's corporate slogan, COMPASS aims to contribute to the realization of "life with a smile" for people around the world.
COMPASS conducts two major activities: the first is an exchange program that allows employees to get to know each other through dialogue sessions with patients and healthcare professionals. The second is activities to understand the realities of diseases and treatment through hands-on experience at medical sites, where employees visit medical sites to understand the needs of patients and other healthcare professionals and to reaffirm their own roles as pharmaceutical company employees.
Activities related to intractable and rare diseases include the following initiatives.
We hold round-table discussions between employees and patients with intractable or rare diseases to hear about their difficulties and requests in their daily lives, and use this information to help employees in their research and development work.
We interview patients and their families, and create a Patient Journey Map together with the participating employees and medical professionals to understand and share the patients' perspectives and feelings.
Screening and distribution of films on rare diseases for employees.
Pfizer employees visit hospitals as part of their training to observe medical examinations and treatments and exchange opinions with healthcare professionals with the consent of the patient. |
| Takeda Pharmaceutical Company Limited | Takeda has concluded a joint research agreement with the Japanese Society for Immunodeficiency and Autoinflammation to utilize the Primary Immunodeficiency Database in Japan (PIDJ), and has been working with the Japan Agency for Medical Research and Development (AMED) to improve the PIDJ registry. We have been working with the AMED to improve the registry.
The registry will enable pharmaceutical companies to utilize quality-assured data for post-marketing surveillance at a relatively low cost, and academia to continue to use the registry as a source of research ideas that will lead to the equalization of patient care and new innovations. |
| Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation has developed drugs for inflammatory bowel disease, multiple sclerosis, and other intractable diseases, providing patients with treatment options. We have also developed a treatment for amyotrophic lateral sclerosis and are expanding its use outside Japan. In addition, we are developing an oral suspension drug to reduce the burden on patients. In addition, we are developing drugs for rare diseases such as erythropoietic protoporphyria and X-linked protoporphyria, which cause painful skin symptoms when exposed to sunlight. https://www.mt-pharma.co.jp/sustainability/social/medical_development.html |
| Pfizer Inc. | Pfizer is actively working to build partnerships with academic researchers and biotech companies on the application of cutting-edge science and technology to bring innovative medicines and vaccines to patients as quickly as possible.
In the area of rare diseases, Pfizer is seeking joint research projects targeting hematological diseases and neuromuscular diseases for the purpose of disease-modifying therapies, elucidation of pathophysiology, and biomarker discovery for those diseases.
Related website:
|